Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

Crescent Biopharma extends cash runway to 2028 with multiple 2027 readouts

Jul 30, 2026, 7:39 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Liquidity improvement via the public offering reduces financing risk; near-term catalysts include ASCEND data in 2027 and China trial progress, which could recalibrate valuation for Crescent’s multi-pronged ADC/ bispecific program.

AI summary

What happened, with direct paths to the underlying reporting

Crescent Biopharma reported Q2 2026 results and extended its cash runway into the second half of 2028 after a $143.7 million public offering. The company also highlighted upcoming ASCEND readouts for CR-001 in 2027 and ongoing China trials for CR-003, with CR-002 IND planned mid-2026 and a global Phase 1/2 start in H2 2026, supporting a longer-term portfolio upside.

Crescent Q2 2026 results show cash runway extended to 2H2028 after $143.7M offering.
ASCEND CR-001 enrollment progressing; multiple data readouts expected in 2027.
Kelun-Biotech exclusive rights to CR-001 in Greater China; IND approved May 2026.
CR-002 IND planned mid-2026; global Phase 1/2 trial in H2 2026.
Cash and pro forma cash as of 6/30/2026: $171.6M and $305.1M, respectively.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.